USA —GT Medical Technologies, a US-based medical equipment manufacturer, has agreed to acquire the radioactive Cesium-131 seed business and its infrastructure from Isoray Medical, a subsidiary of Perspective Therapeutics.
This acquisition aims to fortify GT Medical’s position in the market, particularly in Surgically Targeted Radiation Therapy (STaRT) for brain tumor resection surgeries requiring adjuvant radiation therapy.
The Cesium-131 radioactive seeds are a crucial component of GT Medical’s GammaTile Therapy, a cutting-edge treatment designed for patients undergoing brain tumor resection surgeries.
The therapy utilizes bioresorbable collagen that incorporates Cesium-131 seeds, offering an innovative approach to treating residual tumor cells immediately after surgery.
By acquiring the Cesium-131-related assets, GT Medical ensures direct access and oversight of the production of radioactive seeds, consolidating its market strength and allowing the company to enhance its GammaTile Therapy delivery in the US.
The move is expected to streamline operations, reduce delivery times, and deepen the partnership with the radiation oncologist community.
The acquisition is also set to broaden GT Medical’s customer base, enabling the inclusion of facilities specializing in the treatment of various tumors, including lung, head and neck, prostate, and gynecological tumors.
This expansion aligns with the company’s vision to offer comprehensive solutions for clinicians and patients across diverse medical contexts.
GT Medical Technologies has previously gained US Food and Drug Administration (FDA) approval for GammaTile, making it a valuable asset in treating both newly diagnosed malignant intracranial neoplasms and recurrent intracranial neoplasms.
Since its commercialization in March 2020, GammaTile has been adopted by over 100 brain tumor treatment centers in the US.
The acquisition is anticipated to be finalized in the first quarter of 2024, subject to customary closing conditions.
Through this strategic move, GT Medical aims to create a dominant force in the brachytherapy space, focusing on improved outcomes for patients with multiple tumors using a single best-in-class isotope.
Perspective Therapeutics CEO Thijs Spoor expressed confidence in GT Medical’s commitment to the future of brachytherapy, emphasizing that the transition of Cesium-131 to GT Medical’s hands will allow Perspective Therapeutics to concentrate on advancing its proprietary alpha-particle therapy portfolio.
Cesium-131 brachytherapy has been recognized as a game-changer, offering a more cost-effective and side-effect-reduced alternative compared to traditional treatments.
Studies have indicated its potential in maintaining the quality of life for patients undergoing prostate cancer treatment.
The shorter recuperation periods associated with Cesium-131 allow for quicker recovery of urinary, bowel, and sexual functions, presenting a notable advancement in brachytherapy technology.
GT Medical Technologies CEO Matthew Likens expressed enthusiasm about the acquisition, stating, “By agreeing to acquire Cesium-131-related assets from Isoray, GT Medical Technologies is poised to enhance the delivery of GammaTile Therapy in the US market.”
Likens also highlighted the integration with Isoray’s Cesium-131 brachytherapy team to advance radiation technology and benefit an increasing number of patients.